Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders
Rhee T, Davoudian P, Sanacora G, Wilkinson S. Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders. Drug Discovery Today 2023, 28: 103818. PMID: 37925136, DOI: 10.1016/j.drudis.2023.103818.Peer-Reviewed Original ResearchPsychiatric disordersLysergic acid diethylamideClinical trialsUS Clinical Trials RegistryClinical Trials RegistryPotential therapeutic effectsTrials RegistryTherapeutic effectPotential therapyTherapeutic agentsN-dimethyltryptamineAcid diethylamideLargest causePsychedelic compoundsDisordersPsychotherapeutic approachesSafety concernsTrialsPotential interactive effectsCutting-edge reviewPsychedelic substancesRegistryTherapyShared and Distinct Brain Regions Targeted for Immediate Early Gene Expression by Ketamine and Psilocybin
Davoudian P, Shao L, Kwan A. Shared and Distinct Brain Regions Targeted for Immediate Early Gene Expression by Ketamine and Psilocybin. ACS Chemical Neuroscience 2023, 14: 468-480. PMID: 36630309, PMCID: PMC9898239, DOI: 10.1021/acschemneuro.2c00637.Peer-Reviewed Original ResearchConceptsC-fos expressionBrain regionsNeural plasticityPlasticity-related gene expressionPrimary visual cortexNumerous brain regionsAnterior cingulate cortexExact brain regionsContribution of receptorsDistinct brain regionsImmediate early gene expressionDorsal rapheGlutamatergic receptorsCA1 subfieldSubanesthetic ketamineFemale miceLocus coeruleusInsular cortexSaline controlsTherapeutic effectPsilocybin administrationBasolateral amygdalaLateral habenulaCingulate cortexVisual cortex